Literature DB >> 17476624

Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.

M Ostergaard, J Unkerskov, L Linde, N S Krogh, T Ravn, V S Ringsdal, A Petri, L S Andersen, U Tarp, A Hansen, E Hjardem, M L Hetland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17476624     DOI： 10.1080/03009740601089267

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN： 0300-9742            Impact factor:   3.641


× No keyword cloud information.
  14 in total

Review 1.  Biologics registers in RA: methodological aspects, current role and future applications.

Authors:  Elena Nikiphorou; Maya H Buch; Kimme L Hyrich
Journal:  Nat Rev Rheumatol       Date:  2017-06-01       Impact factor: 20.543

2.  Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Authors:  Elisabeth Hjardem; Mikkel Østergaard; Jan Pødenphant; Ulrik Tarp; Lis Smedegaard Andersen; Jette Bing; Elisabeth Peen; Hanne Merete Lindegaard; Vibeke Stevenius Ringsdal; Anne Rødgaard; Jens Skøt; Annette Hansen; Hans Henrik Mogensen; Janne Unkerskov; Merete Lund Hetland
Journal:  Ann Rheum Dis       Date:  2007-03-27       Impact factor: 19.103

3.  Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.

Authors:  Alejandro Balsa; Juan Víctor Tovar Beltrán; Rafael Cáliz Cáliz; Isabel Mateo Bernardo; Rosario García-Vicuña; Manuel Rodríguez-Gómez; Miguel Angel Belmonte Serrano; Carlos Marras; Eduardo Loza Cortina; Eva Pérez-Pampin; Vicente Vila
Journal:  Rheumatol Int       Date:  2015-03-13       Impact factor: 2.631

Review 4.  Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature.

Authors:  Elizabeth Salt; Susan K Frazier
Journal:  Orthop Nurs       Date:  2010 Jul-Aug       Impact factor: 0.913

Review 5.  Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

Authors:  Joseph R Lutt; Atul Deodhar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  Moetaza M Soliman; Darren M Ashcroft; Kath D Watson; Mark Lunt; Deborah P M Symmons; Kimme L Hyrich
Journal:  Ann Rheum Dis       Date:  2011-02-17       Impact factor: 19.103

Review 7.  Advances in rheumatology: new targeted therapeutics.

Authors:  Paul P Tak; Joachim R Kalden
Journal:  Arthritis Res Ther       Date:  2011-05-25       Impact factor: 5.156

8.  Comparative persistence of the TNF antagonists in rheumatoid arthritis--a population-based cohort study.

Authors:  Anat Fisher; Ken Bassett; James M Wright; M Alan Brookhart; Hugh Freeman; Colin R Dormuth
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

Review 9.  Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers.

Authors:  Anamika Arora; Anadi Mahajan; Dean Spurden; Helen Boyd; Duncan Porter
Journal:  Int J Rheumatol       Date:  2013-10-30

10.  Clinical efficacy of abatacept, tocilizumab, and etanercept in Japanese rheumatoid arthritis patients with inadequate response to anti-TNF monoclonal antibodies.

Authors:  Shinya Hirabara; Nobunori Takahashi; Naoki Fukaya; Hiroyuki Miyake; Yuichiro Yabe; Atsushi Kaneko; Takayasu Ito; Takeshi Oguchi; Daihei Kida; Yuji Hirano; Takayoshi Fujibayashi; Fumiaki Sugiura; Masatoshi Hayashi; Koji Funahashi; Masahiro Hanabayashi; Shuji Asai; Naoki Ishiguro; Toshihisa Kojima
Journal:  Clin Rheumatol       Date:  2014-06-28       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.